ketoconazole has been researched along with valproic acid in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.00) | 18.7374 |
| 1990's | 4 (16.00) | 18.2507 |
| 2000's | 4 (16.00) | 29.6817 |
| 2010's | 15 (60.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Filipek, B; Kamiński, K; Kieć-Kononowicz, K; Latacz, G; Obniska, J; Rapacz, A; Łuszczki, JJ | 1 |
| Andres-Mach, M; Kamiński, K; Kieć-Kononowicz, K; Latacz, G; Rapacz, A; Zagaja, M; Łuszczki, JJ | 1 |
| Karcz, T; Karolak-Wojciechowska, J; Kieć-Kononowicz, K; Kuder, K; Latacz, G; Schwed, JS; Stark, H; Łażewska, D | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kolts, BE; Langfitt, M | 1 |
| Crapo, L; Miller, JW | 1 |
| Eugster, HP; Sengstag, C | 1 |
| Krajewska-Kułak, E; Niczyporuk, W | 1 |
| Dasgupta, A; Luke, M | 1 |
| Chong, CL; Davis, J; Langdon, G; Layton, G; Vourvahis, M; Weissgerber, G | 1 |
| Fasbender, F; Hengstler, JG; Metzler, S; Obholzer, M; Stöber, R; Watzl, C | 1 |
2 review(s) available for ketoconazole and valproic acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The medical treatment of Cushing's syndrome.
Topics: Adrenal Cortex Neoplasms; Adrenal Glands; Aminoglutethimide; Animals; Bromocriptine; Cushing Syndrome; Cyproheptadine; Dogs; Horses; Humans; Ketoconazole; Metyrapone; Mifepristone; Mitotane; Octreotide; Palliative Care; Pituitary Gland; Radiography; Valproic Acid | 1993 |
1 trial(s) available for ketoconazole and valproic acid
| Article | Year |
|---|---|
Effects of ketoconazole and valproic acid on the pharmacokinetics of the next generation NNRTI, lersivirine (UK-453,061), in healthy adult subjects.
Topics: Adult; Antifungal Agents; Area Under Curve; Asian People; Cross-Over Studies; Cytochrome P-450 CYP3A; Drug Interactions; Enzyme Inhibitors; Glucuronosyltransferase; Humans; Ketoconazole; Male; Middle Aged; Nitriles; Pyrazoles; Reverse Transcriptase Inhibitors; Valproic Acid; Young Adult | 2012 |
22 other study(ies) available for ketoconazole and valproic acid
| Article | Year |
|---|---|
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Design, synthesis and biological evaluation of new hybrid anticonvulsants derived from N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2,5-dioxopyrrolidin-1-yl)butanamide derivatives.
Topics: Amides; Animals; Anticonvulsants; Benzylamines; Convulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Electroshock; Humans; Imidazoles; Male; Mice; Microsomes, Liver; Molecular Structure; Motor Activity; Pentylenetetrazole; Propionates; Pyrrolidines; Rotarod Performance Test; Seizures; Small Molecule Libraries; Structure-Activity Relationship | 2015 |
Design, synthesis, and anticonvulsant activity of new hybrid compounds derived from 2-(2,5-dioxopyrrolidin-1-yl)propanamides and 2-(2,5-dioxopyrrolidin-1-yl)butanamides.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Electroshock; HEK293 Cells; Humans; Mice; Models, Molecular; Molecular Structure; Motor Activity; Piperazines; Seizures; Structure-Activity Relationship; Succinimides | 2015 |
Chlorophenoxy aminoalkyl derivatives as histamine H(3)R ligands and antiseizure agents.
Topics: Animals; Anticonvulsants; Dose-Response Relationship, Drug; Electroshock; Humans; Ligands; Male; Mice; Models, Molecular; Molecular Structure; Rats; Rats, Sprague-Dawley; Receptors, Histamine H3; Seizures; Structure-Activity Relationship | 2016 |
Drugs and the liver.
Topics: Acetaminophen; Adult; Aspirin; Chemical and Drug Induced Liver Injury; Chemical and Drug Induced Liver Injury, Chronic; Cholestasis; Cimetidine; Fatty Liver; Female; Hepatic Artery; Hepatic Veins; Humans; Ketoconazole; Liver; Liver Diseases; Liver Neoplasms; Methyldopa; Necrosis; Nitrofurantoin; Peliosis Hepatis; Portal Vein; Valproic Acid; Verapamil | 1984 |
Saccharomyces cerevisiae: an alternative source for human microsomal liver enzymes and its use in drug interaction studies.
Topics: Anticonvulsants; Benzoflavones; Carbamazepine; Cloning, Molecular; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; DNA, Complementary; Drug Interactions; Epoxide Hydrolases; Humans; Ketoconazole; Microsomes, Liver; Oxidoreductases, N-Demethylating; Saccharomyces cerevisiae; Valproic Acid | 1993 |
In vitro synergistic activity of ketoconazole with valproic acid against Candida species.
Topics: Antifungal Agents; Candida; Candida albicans; Candidiasis; Drug Synergism; Humans; Ketoconazole; Microbial Sensitivity Tests; Valproic Acid | 1996 |
Valproic acid-ketoconazole interaction in normal, hypoalbuminemic, and uremic sera: lack of interaction in uremic serum caused by the presence of inhibitor.
Topics: Anticonvulsants; Antifungal Agents; Drug Interactions; Humans; Ketoconazole; Uremia; Valproic Acid | 1997 |
Enhanced activation of human NK cells by drug-exposed hepatocytes.
Topics: Antibodies, Neutralizing; Aspirin; Chemical and Drug Induced Liver Injury; Coculture Techniques; Cytotoxicity Tests, Immunologic; Gene Expression Regulation; Hepatocytes; Histocompatibility Antigens Class I; Humans; Interferon-gamma; Isoniazid; Ketoconazole; Killer Cells, Natural; Natural Cytotoxicity Triggering Receptor 3; NK Cell Lectin-Like Receptor Subfamily K; Valproic Acid | 2020 |